25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ARGX (Argen-X) Stock Analysis
Buy, Hold or Sell?

Let's analyze Argen-X together

I guess you are interested in Argen-X. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Argen-X’s Financial Insights
  • 📈 Technical Analysis (TA) – Argen-X’s Price Targets

I'm going to help you getting a better view of Argen-X. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Argen-X

I send you an email if I find something interesting about Argen-X.

1. Quick Overview

1.1. Quick analysis of Argen-X (30 sec.)










1.2. What can you expect buying and holding a share of Argen-X? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€69.91
Expected worth in 1 year
€121.00
How sure are you?
90.0%

+ What do you gain per year?

Total Gains per Share
€51.10
Return On Investment
7.2%

For what price can you sell your share?

Current Price per Share
€711.20
Expected price per share
€594.80 - €
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Argen-X (5 min.)




Live pricePrice per Share (EOD)
€711.20
Intrinsic Value Per Share
€-73.28 - €103.61
Total Value Per Share
€-3.37 - €173.52

2.2. Growth of Argen-X (5 min.)




Is Argen-X growing?

Current yearPrevious yearGrowGrow %
How rich?$5.3b$4b$1.2b22.8%

How much money is Argen-X making?

Current yearPrevious yearGrowGrow %
Making money$804.1m-$295m$1b136.7%
Net Profit Margin37.0%-24.1%--

How much money comes from the company's main activities?

2.3. Financial Health of Argen-X (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#19 / 844

Most Revenue
#10 / 844

Most Profit
#7 / 844
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Argen-X?

Welcome investor! Argen-X's management wants to use your money to grow the business. In return you get a share of Argen-X.

First you should know what it really means to hold a share of Argen-X. And how you can make/lose money.

Speculation

The Price per Share of Argen-X is €711.20. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Argen-X.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Argen-X, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €69.91. Based on the TTM, the Book Value Change Per Share is €12.77 per quarter. Based on the YOY, the Book Value Change Per Share is €17.90 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Argen-X.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps12.341.7%12.341.7%-4.79-0.7%-1.33-0.2%-4.10-0.6%-2.56-0.4%
Usd Book Value Change Per Share14.882.1%14.882.1%20.852.9%13.421.9%12.451.8%8.041.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share14.882.1%14.882.1%20.852.9%13.421.9%12.451.8%8.041.1%
Usd Price Per Share698.88-698.88-400.11-501.56-430.77-251.31-
Price to Earnings Ratio56.65-56.65--83.49--20.68--29.19--53.43-
Price-to-Total Gains Ratio46.97-46.97-19.19-51.85-43.40-28.08-
Price to Book Ratio8.58-8.58-6.01-7.82-8.55-10.73-
Price-to-Total Gains Ratio46.97-46.97-19.19-51.85-43.40-28.08-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share828.40576
Number of shares1
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share14.8812.45
Usd Total Gains Per Share14.8812.45
Gains per Quarter (1 shares)14.8812.45
Gains per Year (1 shares)59.5249.81
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10605005040
20119110010090
301791700149140
402382300199190
502982900249240
603573500299290
704174100349340
804764700398390
905365300448440
1005955900498490

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%1.02.00.033.3%1.04.00.020.0%1.09.00.010.0%1.013.00.07.1%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%9.01.00.090.0%12.02.00.085.7%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%0.00.014.00.0%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%9.01.00.090.0%12.02.00.085.7%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Argen-X compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--12.77412.7740%17.901-29%11.524+11%10.690+19%6.906+85%
Book Value Per Share--69.90869.9080%57.134+22%55.425+26%44.991+55%25.727+172%
Current Ratio--7.2897.2890%9.749-25%8.739-17%8.184-11%8.699-16%
Debt To Asset Ratio--0.1140.1140%0.098+16%0.105+9%0.138-18%0.169-33%
Debt To Equity Ratio--0.1240.1240%0.109+14%0.115+7%0.166-26%0.225-45%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--41423800583.84141423800583.8410%23496831721.500+76%29324063070.714+41%25042711930.188+65%14606087090.967+184%
Eps--10.59210.5920%-4.114+139%-1.139+111%-3.519+133%-2.195+121%
Ev To Ebitda Ratio---2956.036-2956.0360%-142.339-95%-1047.163-65%-647.079-78%-360.627-88%
Ev To Sales Ratio--22.19622.1960%22.319-1%36.628-39%122.792-82%131.651-83%
Free Cash Flow Per Share---1.114-1.1140%-6.472+481%-7.021+530%-7.369+562%-3.694+232%
Free Cash Flow To Equity Per Share--2.5712.5710%12.167-79%4.342-41%4.899-48%4.430-42%
Gross Profit Margin--0.6180.6180%1.685-63%1.156-47%1.123-45%1.070-42%
Intrinsic Value_10Y_max--103.613----------
Intrinsic Value_10Y_min---73.283----------
Intrinsic Value_1Y_max---0.661----------
Intrinsic Value_1Y_min---7.438----------
Intrinsic Value_3Y_max--6.431----------
Intrinsic Value_3Y_min---22.399----------
Intrinsic Value_5Y_max--23.670----------
Intrinsic Value_5Y_min---37.301----------
Market Cap43787820171.200+11%39106688400.00039106688400.0000%21148926081.000+85%27233357135.600+44%23202486773.320+69%13500090633.426+190%
Net Profit Margin--0.3700.3700%-0.241+165%-0.533+244%-3.434+1028%-2.704+831%
Operating Margin---0.008-0.0080%-0.248+2916%-0.675+8127%-3.499+42529%-2.799+34000%
Operating Ratio--1.0251.0250%1.347-24%1.708-40%5.913-83%5.716-82%
Pb Ratio10.173+16%8.5838.5830%6.012+43%7.824+10%8.553+0%10.728-20%
Pe Ratio67.146+16%56.64856.6480%-83.493+247%-20.682+137%-29.191+152%-53.434+194%
Price Per Share711.200+16%600.000600.0000%343.500+75%430.600+39%369.820+62%215.751+178%
Price To Free Cash Flow Ratio-638.628-19%-538.775-538.7750%-53.076-90%-205.897-62%-138.349-74%-71.660-87%
Price To Total Gains Ratio55.676+16%46.97046.9700%19.189+145%51.846-9%43.397+8%28.077+67%
Quick Ratio--9.5369.5360%11.372-16%11.228-15%10.673-11%12.019-21%
Return On Assets--0.1340.1340%-0.065+148%-0.052+139%-0.113+184%-0.141+205%
Return On Equity--0.1460.1460%-0.072+149%-0.059+141%-0.141+196%-0.181+224%
Total Gains Per Share--12.77412.7740%17.901-29%11.524+11%10.690+19%6.906+85%
Usd Book Value--5307390675.1425307390675.1420%4097428327.866+30%4072821326.662+30%3285331636.221+62%1874411558.207+183%
Usd Book Value Change Per Share--14.87914.8790%20.851-29%13.423+11%12.452+19%8.044+85%
Usd Book Value Per Share--81.42981.4290%66.550+22%64.560+26%52.406+55%29.967+172%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--48250442920.05748250442920.0570%27369109589.203+76%34156668664.767+41%29169750856.283+65%17013170243.558+184%
Usd Eps--12.33712.3370%-4.792+139%-1.327+111%-4.099+133%-2.557+121%
Usd Free Cash Flow---84546376.678-84546376.6780%-464130088.531+449%-505095968.638+497%-529422834.886+526%-265411067.063+214%
Usd Free Cash Flow Per Share---1.297-1.2970%-7.538+481%-8.178+530%-8.584+562%-4.303+232%
Usd Free Cash Flow To Equity Per Share--2.9952.9950%14.172-79%5.057-41%5.706-48%5.160-42%
Usd Market Cap51004052935.414+11%45551470648.32045551470648.3200%24634269099.149+85%31721414391.547+44%27026256593.563+69%15724905569.815+190%
Usd Price Per Share828.406+16%698.880698.8800%400.109+75%501.563+39%430.766+62%251.307+178%
Usd Profit--804118072.637804118072.6370%-295047334.982+137%-66836546.047+108%-243442023.423+130%-154754517.877+119%
Usd Revenue--2173851507.2502173851507.2500%1226292454.733+77%1270294358.547+71%869878547.211+150%451907914.701+381%
Usd Total Gains Per Share--14.87914.8790%20.851-29%13.423+11%12.452+19%8.044+85%
 EOD+5 -3MRQTTM+0 -0YOY+22 -163Y+25 -135Y+28 -1010Y+29 -9

3.3 Fundamental Score

Let's check the fundamental score of Argen-X based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1567.146
Price to Book Ratio (EOD)Between0-110.173
Net Profit Margin (MRQ)Greater than00.370
Operating Margin (MRQ)Greater than0-0.008
Quick Ratio (MRQ)Greater than19.536
Current Ratio (MRQ)Greater than17.289
Debt to Asset Ratio (MRQ)Less than10.114
Debt to Equity Ratio (MRQ)Less than10.124
Return on Equity (MRQ)Greater than0.150.146
Return on Assets (MRQ)Greater than0.050.134
Total6/10 (60.0%)

3.4 Technical Score

Let's check the technical score of Argen-X based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5071.945
Ma 20Greater thanMa 50659.120
Ma 50Greater thanMa 100624.428
Ma 100Greater thanMa 200562.503
OpenGreater thanClose702.200
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About Argen-X

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren's disease, lupus nephropathy, systemic sclerosis, antibody-mediated rejection, and autoimmune encephalitis; empasiprubart for multifocal motor neuropath, CIDP, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome, amyotrophic lateral sclerosis, and spinal muscular atrophy. In addition, the company is also developing ARGX-119, a MuSK agonist to treat congenital myasthenic syndromes and amyotrophic lateral sclerosis; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121 and ARGX 220 that targets the immune system; ARGX-213, which targets FcRn; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic collaborations with OncoVerity, Inc, LEO Pharma A/S, Zai Lab Limited, AbbVie, Inc., Elektrofi, Genmab SE, Chugai Pharmaceutical Co., Ltd., Clayton Foundation, Halozyme Therapeutics, Inc., AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Lonza Sales AG, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, and IQVIA Ltd. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Fundamental data was last updated by Penke on 2025-10-15 13:40:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Argen-X earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Argen-X to the Biotechnology industry mean.
  • A Net Profit Margin of 37.0% means that €0.37 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Argen-X:

  • The MRQ is 37.0%. The company is making a huge profit. +2
  • The TTM is 37.0%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ37.0%TTM37.0%0.0%
TTM37.0%YOY-24.1%+61.1%
TTM37.0%5Y-343.4%+380.4%
5Y-343.4%10Y-270.4%-73.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ37.0%-70.7%+107.7%
TTM37.0%-161.7%+198.7%
YOY-24.1%-189.8%+165.7%
3Y-53.3%-262.6%+209.3%
5Y-343.4%-338.6%-4.8%
10Y-270.4%-473.1%+202.7%
4.3.1.2. Return on Assets

Shows how efficient Argen-X is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Argen-X to the Biotechnology industry mean.
  • 13.4% Return on Assets means that Argen-X generated €0.13 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Argen-X:

  • The MRQ is 13.4%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 13.4%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ13.4%TTM13.4%0.0%
TTM13.4%YOY-6.5%+19.9%
TTM13.4%5Y-11.3%+24.8%
5Y-11.3%10Y-14.1%+2.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ13.4%-11.9%+25.3%
TTM13.4%-11.9%+25.3%
YOY-6.5%-11.2%+4.7%
3Y-5.2%-12.0%+6.8%
5Y-11.3%-12.0%+0.7%
10Y-14.1%-14.0%-0.1%
4.3.1.3. Return on Equity

Shows how efficient Argen-X is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Argen-X to the Biotechnology industry mean.
  • 14.6% Return on Equity means Argen-X generated €0.15 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Argen-X:

  • The MRQ is 14.6%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 14.6%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ14.6%TTM14.6%0.0%
TTM14.6%YOY-7.2%+21.8%
TTM14.6%5Y-14.1%+28.7%
5Y-14.1%10Y-18.1%+4.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ14.6%-14.2%+28.8%
TTM14.6%-14.8%+29.4%
YOY-7.2%-15.3%+8.1%
3Y-5.9%-16.8%+10.9%
5Y-14.1%-17.4%+3.3%
10Y-18.1%-19.8%+1.7%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Argen-X.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Argen-X is operating .

  • Measures how much profit Argen-X makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Argen-X to the Biotechnology industry mean.
  • An Operating Margin of -0.8% means the company generated €-0.01  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Argen-X:

  • The MRQ is -0.8%. The company is operating very inefficient. -2
  • The TTM is -0.8%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-0.8%TTM-0.8%0.0%
TTM-0.8%YOY-24.8%+23.9%
TTM-0.8%5Y-349.9%+349.1%
5Y-349.9%10Y-279.9%-70.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.8%-153.1%+152.3%
TTM-0.8%-265.6%+264.8%
YOY-24.8%-249.5%+224.7%
3Y-67.5%-248.8%+181.3%
5Y-349.9%-331.9%-18.0%
10Y-279.9%-489.0%+209.1%
4.3.2.2. Operating Ratio

Measures how efficient Argen-X is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.02 means that the operating costs are €1.02 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Argen-X:

  • The MRQ is 1.025. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.025. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.025TTM1.0250.000
TTM1.025YOY1.347-0.322
TTM1.0255Y5.913-4.889
5Y5.91310Y5.716+0.197
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0251.861-0.836
TTM1.0252.793-1.768
YOY1.3472.852-1.505
3Y1.7083.559-1.851
5Y5.9134.633+1.280
10Y5.7166.269-0.553
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Argen-X.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Argen-X is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 7.29 means the company has €7.29 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Argen-X:

  • The MRQ is 7.289. The company is very able to pay all its short-term debts. +2
  • The TTM is 7.289. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ7.289TTM7.2890.000
TTM7.289YOY9.749-2.460
TTM7.2895Y8.184-0.895
5Y8.18410Y8.699-0.515
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.2893.431+3.858
TTM7.2893.644+3.645
YOY9.7494.060+5.689
3Y8.7394.456+4.283
5Y8.1845.742+2.442
10Y8.6996.132+2.567
4.4.3.2. Quick Ratio

Measures if Argen-X is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Argen-X to the Biotechnology industry mean.
  • A Quick Ratio of 9.54 means the company can pay off €9.54 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Argen-X:

  • The MRQ is 9.536. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 9.536. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ9.536TTM9.5360.000
TTM9.536YOY11.372-1.835
TTM9.5365Y10.673-1.136
5Y10.67310Y12.019-1.347
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.5362.911+6.625
TTM9.5363.133+6.403
YOY11.3723.831+7.541
3Y11.2284.337+6.891
5Y10.6735.697+4.976
10Y12.0196.537+5.482
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Argen-X.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Argen-X assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Argen-X to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.11 means that Argen-X assets are financed with 11.4% credit (debt) and the remaining percentage (100% - 11.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Argen-X:

  • The MRQ is 0.114. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.114. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.114TTM0.1140.000
TTM0.114YOY0.098+0.016
TTM0.1145Y0.138-0.025
5Y0.13810Y0.169-0.031
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1140.344-0.230
TTM0.1140.364-0.250
YOY0.0980.335-0.237
3Y0.1050.344-0.239
5Y0.1380.349-0.211
10Y0.1690.379-0.210
4.5.4.2. Debt to Equity Ratio

Measures if Argen-X is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Argen-X to the Biotechnology industry mean.
  • A Debt to Equity ratio of 12.4% means that company has €0.12 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Argen-X:

  • The MRQ is 0.124. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.124. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.124TTM0.1240.000
TTM0.124YOY0.109+0.015
TTM0.1245Y0.166-0.043
5Y0.16610Y0.225-0.058
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1240.401-0.277
TTM0.1240.445-0.321
YOY0.1090.435-0.326
3Y0.1150.471-0.356
5Y0.1660.467-0.301
10Y0.2250.517-0.292
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Argen-X generates.

  • Above 15 is considered overpriced but always compare Argen-X to the Biotechnology industry mean.
  • A PE ratio of 56.65 means the investor is paying €56.65 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Argen-X:

  • The EOD is 67.146. Based on the earnings, the company is expensive. -2
  • The MRQ is 56.648. Based on the earnings, the company is expensive. -2
  • The TTM is 56.648. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD67.146MRQ56.648+10.499
MRQ56.648TTM56.6480.000
TTM56.648YOY-83.493+140.140
TTM56.6485Y-29.191+85.839
5Y-29.19110Y-53.434+24.243
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD67.146-2.840+69.986
MRQ56.648-2.312+58.960
TTM56.648-2.654+59.302
YOY-83.493-3.619-79.874
3Y-20.682-3.736-16.946
5Y-29.191-5.803-23.388
10Y-53.434-6.948-46.486
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Argen-X:

  • The EOD is -638.628. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -538.775. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -538.775. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-638.628MRQ-538.775-99.853
MRQ-538.775TTM-538.7750.000
TTM-538.775YOY-53.076-485.699
TTM-538.7755Y-138.349-400.426
5Y-138.34910Y-71.660-66.689
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-638.628-3.555-635.073
MRQ-538.775-2.911-535.864
TTM-538.775-3.693-535.082
YOY-53.076-4.195-48.881
3Y-205.897-5.149-200.748
5Y-138.349-8.425-129.924
10Y-71.660-9.923-61.737
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Argen-X is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 8.58 means the investor is paying €8.58 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Argen-X:

  • The EOD is 10.173. Based on the equity, the company is expensive. -2
  • The MRQ is 8.583. Based on the equity, the company is overpriced. -1
  • The TTM is 8.583. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD10.173MRQ8.583+1.591
MRQ8.583TTM8.5830.000
TTM8.583YOY6.012+2.571
TTM8.5835Y8.553+0.030
5Y8.55310Y10.728-2.176
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD10.1732.487+7.686
MRQ8.5832.063+6.520
TTM8.5832.237+6.346
YOY6.0122.444+3.568
3Y7.8242.657+5.167
5Y8.5533.804+4.749
10Y10.7284.517+6.211
4.6.2. Total Gains per Share

2.4. Latest News of Argen-X

Does Argen-X still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Argen-X to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-10-12
13:09
Analyzing argenx (ENXTBR:ARGX) Valuation Following Recent Share Price StrengthRead
2025-10-03
22:01
argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025Read
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2020-12-312021-12-312022-12-312023-12-312024-12-31
Income before Tax  -519,695176,515-343,179-282,937-626,116364,706-261,410334,53773,127
Net Income  -522,359171,863-350,496-258,691-609,186355,883-253,303943,652690,349
Net Income from Continuing Operations  -454,080103,585-350,496-258,691-609,186407,871-201,316916,481715,165



6.2. Latest Balance Sheet

Balance Sheet of 2024-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets5,987,294
Total Liabilities679,802
Total Stockholder Equity5,498,283
 As reported
Total Liabilities 679,802
Total Stockholder Equity+ 5,498,283
Total Assets = 5,987,294

Assets

Total Assets5,987,294
Total Current Assets4,713,659
Long-term Assets1,273,635
Total Current Assets
Cash And Cash Equivalents 1,447,888
Short-term Investments 1,878,890
Net Receivables 909,096
Inventory 407,233
Other Current Assets 18,504
Total Current Assets  (as reported)4,713,659
Total Current Assets  (calculated)4,661,612
+/- 52,048
Long-term Assets
Property Plant Equipment 43,518
Long Term Investments 49,697
Intangible Assets 181,445
Long-term Assets Other 78,198
Long-term Assets  (as reported)1,273,635
Long-term Assets  (calculated)352,858
+/- 920,777

Liabilities & Shareholders' Equity

Total Current Liabilities646,670
Long-term Liabilities33,132
Total Stockholder Equity5,498,283
Total Current Liabilities
Short-term Debt 6,306
Accounts payable 482,702
Other Current Liabilities 144,272
Total Current Liabilities  (as reported)646,670
Total Current Liabilities  (calculated)633,280
+/- 13,390
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt32,747
Long-term Liabilities  (as reported)33,132
Long-term Liabilities  (calculated)32,747
+/- 385
Total Stockholder Equity
Common Stock7,227
Retained Earnings -1,571,804
Accumulated Other Comprehensive Income 66,713
Other Stockholders Equity 6,996,147
Total Stockholder Equity (as reported)5,498,283
Total Stockholder Equity (calculated)5,498,283
+/-0
Other
Capital Stock7,227
Cash and Short Term Investments 3,378,826
Common Stock Shares Outstanding 65,178
Liabilities and Stockholders Equity 6,202,522
Net Debt -1,410,190
Net Invested Capital 5,498,283
Net Working Capital 4,213,187
Property Plant and Equipment Gross 72,716
Short Long Term Debt Total 37,698



6.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-31
> Total Assets 
12,261
31,941
22,930
34,540
71,149
50,250
111,241
444,979
661,700
1,610,215
2,279,407
2,850,274
3,134,261
4,542,458
5,987,294
5,987,2944,542,4583,134,2612,850,2742,279,4071,610,215661,700444,979111,24150,25071,14934,54022,93031,94112,261
   > Total Current Assets 
11,892
31,569
22,479
33,731
69,771
48,255
107,056
440,056
654,819
1,542,675
2,057,001
2,542,971
2,774,197
4,123,737
4,713,659
4,713,6594,123,7372,774,1972,542,9712,057,0011,542,675654,819440,056107,05648,25569,77133,73122,47931,56911,892
       Cash And Cash Equivalents 
10,501
30,515
20,406
31,373
39,131
38,828
94,545
228,984
321,482
372,162
1,216,803
1,334,676
800,740
2,048,844
1,447,888
1,447,8882,048,844800,7401,334,6761,216,803372,162321,482228,98494,54538,82839,13131,37320,40630,51510,501
       Short-term Investments 
0
0
1,389
690
28,933
7,449
7,184
202,638
324,330
1,128,499
779,649
1,002,052
1,391,808
1,131,000
1,878,890
1,878,8901,131,0001,391,8081,002,052779,6491,128,499324,330202,6387,1847,44928,9336901,38900
       Net Receivables 
1,386
986
569
1,519
1,595
1,483
2,243
3,599
3,646
31,878
6,081
38,221
277,275
499,271
909,096
909,096499,271277,27538,2216,08131,8783,6463,5992,2431,4831,5951,5195699861,386
       Inventory 
0
0
0
0
0
0
0
0
0
-1,022,312
25,195
109,076
228,353
310,550
407,233
407,233310,550228,353109,07625,195-1,022,312000000000
       Other Current Assets 
5
67
115
148
112
496
3,084
4,835
5,361
10,136
29,273
58,946
76,021
134,072
18,504
18,504134,07276,02158,94629,27310,1365,3614,8353,084496112148115675
   > Long-term Assets 
369
372
451
809
1,379
1,995
4,185
4,924
6,881
67,540
222,406
307,303
360,064
418,721
1,273,635
1,273,635418,721360,064307,303222,40667,5406,8814,9244,1851,9951,379809451372369
       Property Plant Equipment 
328
356
231
166
202
272
806
811
943
9,175
11,582
15,843
16,235
22,676
43,518
43,51822,67616,23515,84311,5829,175943811806272202166231356328
       Long Term Investments 
0
0
0
1
1
1
1
1
1
2,596
5,140
53,169
40,481
47,155
49,697
49,69747,15540,48153,1695,1402,596111111000
       Intangible Assets 
41
16
0
0
9
8
18
16
64
45,117
167,344
171,684
174,901
125,228
181,445
181,445125,228174,901171,684167,34445,11764161889001641
       Long-term Assets Other 
0
0
218
642
1,167
1,714
3,360
4,096
5,873
10,332
22,135
34,416
49,225
126,451
78,198
78,198126,45149,22534,41622,13510,3325,8734,0963,3601,7141,16764221800
> Total Liabilities 
2,029
4,043
6,278
4,568
10,249
9,494
44,590
31,165
45,828
429,806
605,356
316,050
320,562
444,951
679,802
679,802444,951320,562316,050605,356429,80645,82831,16544,5909,49410,2494,5686,2784,0432,029
   > Total Current Liabilities 
2,029
4,043
6,278
4,569
10,249
9,494
33,998
29,413
45,820
179,696
328,493
301,239
302,277
422,993
646,670
646,670422,993302,277301,239328,493179,69645,82029,41333,9989,49410,2494,5696,2784,0432,029
       Short-term Debt 
0
2,193
2,238
0
0
0
0
0
0
2,218
3,476
3,509
3,417
4,646
6,306
6,3064,6463,4173,5093,4762,2180000002,2382,1930
       Accounts payable 
1,690
363
1,850
1,241
2,005
4,967
4,612
5,273
27,628
65,639
206,325
208,850
188,721
245,557
482,702
482,702245,557188,721208,850206,32565,63927,6285,2734,6124,9672,0051,2411,8503631,690
       Other Current Liabilities 
0
3,680
3,858
2,698
4,047
0
8,210
13,065
14,779
30,188
68,867
84,565
106,958
168,456
144,272
144,272168,456106,95884,56568,86730,18814,77913,0658,21004,0472,6983,8583,6800
   > Long-term Liabilities 
2,028
2,556
4,661
-1
6,218
6,599
10,592
1,752
8
250,110
276,863
14,811
18,285
21,958
33,132
33,13221,95818,28514,811276,863250,11081,75210,5926,5996,218-14,6612,5562,028
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
4,540
0
0
0
0
0
000004,540000000000
       Other Liabilities 
0
0
0
0
0
0
10,071
1,460
7
245,009
270,682
6,855
9,276
0
0
009,2766,855270,682245,00971,46010,071000000
> Total Stockholder Equity
10,232
27,898
16,652
29,972
60,900
40,756
66,651
413,815
615,872
1,180,409
1,674,051
2,534,224
2,813,699
4,097,507
5,498,283
5,498,2834,097,5072,813,6992,534,2241,674,0511,180,409615,872413,81566,65140,75660,90029,97216,65227,89810,232
   Common Stock
248
439
448
643
1,910
1,727
2,116
3,859
4,115
5,209
5,744
6,233
6,201
7,058
7,227
7,2277,0586,2016,2335,7445,2094,1153,8592,1161,7271,910643448439248
   Retained Earnings -1,571,804-2,404,844-2,109,791-1,400,197-991,932-383,477-194,009-120,652-76,240-55,887-43,541-35,200-25,604-12,523-8,410
   Accumulated Other Comprehensive Income 
297
540
1,562
1,969
2,890
5,081
7,884
14,113
35,400
53,036
321,206
92,394
71,723
72,071
66,713
66,71372,07171,72392,394321,20653,03635,40014,1137,8845,0812,8901,9691,562540297
   Capital Surplus 
0
0
0
0
0
82,169
126,358
430,518
673,454
1,308,539
0
0
0
0
0
000001,308,539673,454430,518126,35882,16900000
   Treasury Stock000000000000000
   Other Stockholders Equity 
18,097
39,441
40,245
62,559
99,640
89,836
132,891
516,494
770,366
1,505,641
2,339,033
3,836,551
4,845,566
6,423,222
6,996,147
6,996,1476,423,2224,845,5663,836,5512,339,0331,505,641770,366516,494132,89189,83699,64062,55940,24539,44118,097



6.4. Balance Sheets

Currency in USD. All numbers in thousands.




6.5. Cash Flows

Currency in USD. All numbers in thousands.




6.6. Income Statements

Currency in USD. All numbers in thousands.


6.7. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue2,173,893
Cost of Revenue-1,168,700
Gross Profit1,005,1931,005,193
 
Operating Income (+$)
Gross Profit1,005,193
Operating Expense-1,059,147
Operating Income-21,654-53,954
 
Operating Expense (+$)
Research Development949,298
Selling General Administrative745,201
Selling And Marketing Expenses306,987
Operating Expense1,059,1472,001,486
 
Net Interest Income (+$)
Interest Income138,740
Interest Expense-2,464
Other Finance Cost-0
Net Interest Income136,276
 
Pretax Income (+$)
Operating Income-21,654
Net Interest Income136,276
Other Non-Operating Income Expenses0
Income Before Tax (EBT)85,180-128,488
EBIT - interestExpense = -20,308
56,274
806,598
Interest Expense2,464
Earnings Before Interest and Taxes (EBIT)-17,84487,644
Earnings Before Interest and Taxes (EBITDA)-16,323
 
After tax Income (+$)
Income Before Tax85,180
Tax Provision--747,860
Net Income From Continuing Ops833,040833,040
Net Income804,134
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses2,269,859
Total Other Income/Expenses Net106,834-136,276
 

Technical Analysis of Argen-X
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Argen-X. The general trend of Argen-X is BULLISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Argen-X's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (85.7%) Bearish trend (-85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Argen-X Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Argen-X.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: .

The bearish price targets are: 664.80 > 658.00 > 594.80.

Know someone who trades $ARGX? Share this with them.👇

Argen-X Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Argen-X. The current mas is .

The long score for the Moving Averages is 13/14.
The longshort score for the Moving Averages is 12/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Argen-X Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Argen-X. The current macd is 23.59.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Argen-X price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Argen-X. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Argen-X price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Argen-X Daily Moving Average Convergence/Divergence (MACD) ChartArgen-X Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Argen-X. The current adx is 34.88.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Argen-X shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Argen-X Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Argen-X. The current sar is 661.43.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Argen-X Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Argen-X. The current rsi is 71.95. The current phase is Overbought in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Overbought in bull market: Short-term excessive buying, potential for pullback. Consider taking profits, be cautious of potential correction. -1
  • Trending up: The RSI is trending up. +1
Argen-X Daily Relative Strength Index (RSI) ChartArgen-X Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Argen-X. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 5/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Argen-X price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Argen-X Daily Stochastic Oscillator ChartArgen-X Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Argen-X. The current cci is 103.65.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Argen-X Daily Commodity Channel Index (CCI) ChartArgen-X Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Argen-X. The current cmo is 48.47.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Argen-X Daily Chande Momentum Oscillator (CMO) ChartArgen-X Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Argen-X. The current willr is -2.41635688.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Argen-X Daily Williams %R ChartArgen-X Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Argen-X.

Argen-X Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Argen-X. The current atr is 16.70.

Argen-X Daily Average True Range (ATR) ChartArgen-X Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Argen-X. The current obv is 3,472,257.

Argen-X Daily On-Balance Volume (OBV) ChartArgen-X Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Argen-X. The current mfi is 85.82.

The long score for the Money Flow Index (MFI) is 2/2.
The longshort score for the Money Flow Index (MFI) is 2/(-2 +2).

  • MFI > 50: +1
  • MFI > 80: +1
Argen-X Daily Money Flow Index (MFI) ChartArgen-X Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Argen-X.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-06-03STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-04STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-06SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-09STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-10CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-06-13WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-06-18STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-24RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-26STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-30WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-01STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-02WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-03STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-07-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-08STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-07-10DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-14CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-15STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-17STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-23STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-24CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-07-25BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-07-29STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-31STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-08-01MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-08-04MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-08-05STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-06STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-08-07RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-08-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-08-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-08-18STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-19STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-21STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-25STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-08-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-01STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-02STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-03STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-04BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-08MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-09-09STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-09-15RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-09-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-09-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-09-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-09-22STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-23STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-09-24CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-09-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-09-26STOCH SHORT EXITThe %K line crosses above the %D line.
2025-10-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-10-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-10-03STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-10-06STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-10-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-10-08STOCH SHORT EXITThe %K line crosses above the %D line.
2025-10-09MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-10-10RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-10-13STOCH SHORT EXITThe %K line crosses above the %D line.
2025-10-14RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-10-15STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-10-16CCI LONG ENTRY SHORT CLOSE100 crossover to upside

6.3. Candlestick Patterns

Argen-X Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Argen-X based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5071.945
Ma 20Greater thanMa 50659.120
Ma 50Greater thanMa 100624.428
Ma 100Greater thanMa 200562.503
OpenGreater thanClose702.200
Total3/5 (60.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Argen-X with someone you think should read this too:
  • Are you bullish or bearish on Argen-X? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Argen-X? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Argen-X

I send you an email if I find something interesting about Argen-X.


Comments

How you think about this?

Leave a comment

Stay informed about Argen-X.

Receive notifications about Argen-X in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.